Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

29.95
-1.5800-5.01%
Pre-market: 30.020.0700+0.23%05:27 EDT
Volume:2.81M
Turnover:84.44M
Market Cap:3.49B
PE:-6.42
High:31.25
Open:31.21
Low:29.70
Close:31.53
52wk High:43.15
52wk Low:22.96
Shares:116.65M
Float Shares:110.00M
Volume Ratio:1.45
T/O Rate:2.55%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:8.56
PE(LYR):-9.38

Loading ...

Viking Therapeutics reports Q2 EPS ($1.10) vs. (58c) last year

TIPRANKS
·
Jul 30

Viking Therapeutics Q2 EPS $(1.10) Beats $(1.25) Estimate

Benzinga Earnings
·
Jul 30

Viking Therapeutics Q2 EPS USD -1.1 Vs. IBES Estimate USD -1.25

Reuters
·
Jul 30

Viking Therapeutics (VKTX) Stock Looks Above Fair Value Today

Simply Wall St.
·
Jul 30

Viking Therapeutics options imply 8.1% move in share price post-earnings

TIPRANKS
·
Jul 30

Viking Therapeutics Inc Expected to Post a Loss of $1.25 a Share - Earnings Preview

Reuters
·
Jul 28

Analysts Offer Insights on Healthcare Companies: Viking Therapeutics (VKTX), Summit Therapeutics (SMMT) and Progyny (PGNY)

TIPRANKS
·
Jul 24

Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors

THOMSON REUTERS
·
Jul 23

Viking Therapeutics to Report Q2 Results After Market Close, Host Conference Call

Reuters
·
Jul 23

Viking Therapeutics (VKTX) Could Be 61% Undervalued As It Starts VK3019 Trial

Simply Wall St.
·
Jul 18

VKTX: Buy Rating Backed by VK2735’s Potential to Transform Obesity Maintenance Therapy Ahead of Key Phase I Data

TIPRANKS
·
Jul 17

Viking Therapeutics Posts Corporate Presentation Highlighting Vk2735 Obesity Drug Program Pipeline

Reuters
·
Jul 15

Does Viking Therapeutics (VKTX) Expanding Into Dual-Agonist Obesity Drugs Reframe Its Long-Term Pipeline Strategy?

Simply Wall St.
·
Jul 10

Movement Alert|Viking Therapeutics Rises 8.68% in Regular Trading, Phase 1 Clinical Trial of Novel Weight Loss Drug VK3019 Boosts Market Sentiment

Market Focus
·
Jul 08

Race to Launch Weight-loss Pills Heats up as Smaller Players Advance

Reuters
·
Jul 08

Trump’s FDA May Soon Throw Its Weight Behind Peptides. Should You Buy In?

Macro World​
·
Jul 06

Cantor Fitzgerald Remains a Buy on Viking Therapeutics (VKTX)

TIPRANKS
·
Jul 01

Viking Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
Jun 25

Viking Therapeutics on Pace for Highest Close Since November 2025

Dow Jones
·
Jun 25

Analysts Are Bullish on Top Healthcare Stocks: Silexion Therapeutics (SLXN), Viking Therapeutics (VKTX)

TIPRANKS
·
Jun 25